Novel diagnostics & biomarkers in for DLBCL and CTCL

Novel diagnostics & biomarkers in for DLBCL and CTCL

VJHemOnc

1 year
87 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this session, Thomas Habermann, MD, of the Mayo Clinic, Rochester, MI, chairs a discussion with Bjoern Chapuy, PhD, MD, from the Dana-Farber Cancer Institute, Boston, MA, and Nicolas Ortonne, MD, PhD, of Henri Mondor University Hospital, Créteil, France. The group explore actionable genetic signatures for diffuse large B-cell lymphoma, and biomarkers for the diagnosis and treatment of cutaneous T-cell lymphoma. This discussion was recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France.
Up Next Autoplay
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
0 Views
cancergrace 2 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
2 Views
Cancer-News 3 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
1 Views
Cancer-News 3 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
1 Views
Cancer-News 3 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 3 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
1 Views
Massachusetts General Hospital 3 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
1 Views
Cancer-News 3 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 3 days
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
2 Views
Cancer-News 3 days
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
Category: Brain Cancer
4 Views
Massachusetts General Hospital 3 days